

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.ustnb.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/796,825	03/09/2004	Gudarz Davar	50073/010003 2455		
21559 CLARK & EL	7590 05/14/2 BING LLP	EXAM	EXAMINER		
101 FEDERA	L STREET		KIM, JENNIFER M		
BOSTON, MA	A 02110		ART UNIT PAPER NUMBER		
			1617		
			MAIL DATE	DELIVERY MODE	
		•	05/14/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	•				
Office Action Summary		Application	No.	Applicant(s)	
		10/796,825	10/796,825 DAVAR ET AL.		
		Examiner		Art Unit	
		Jennifer Kin	า	1617	
Period fo	The MAILING DATE of this communi or Reply	ication appears on the (over sheet with the	correspondence address	
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE Mansions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this common operiod for reply is specified above, the maximum starre to reply within the set or extended period for reply reply received by the Office later than three months a led patent term adjustment. See 37 CFR 1.704(b).	AILING DATE OF THI- of 37 CFR 1.136(a). In no even nunication. atutory period will apply and will- will, by statute, cause the applic	S COMMUNICATIO t, however, may a reply be ti expire SIX (6) MONTHS from ation to become ABANDON	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).	
Status					
1)🛛	Responsive to communication(s) file	ed on <u>09 March 2004</u> .			
2a) <u></u> □	This action is FINAL .	2b)⊡ This action is no	n-final.		
3)□	Since this application is in condition	for allowance except for	or formal matters, pr	osecution as to the merits is	
	closed in accordance with the practic	ce under <i>Ex parte Qua</i>	yle, 1935 C.D. 11, 4	53 O.G. 213.	
Disposit	ion of Claims				
4)⊠	Claim(s) 1-26 is/are pending in the a	application.			
	4a) Of the above claim(s) is/a	re withdrawn from con	sideration.		
5)[Claim(s) is/are allowed.				
	Claim(s) is/are rejected.				
'=	Claim(s) is/are objected to.				
8)⊠	Claim(s) <u>1-26</u> are subject to restriction	on and/or election requ	irement.		•
Applicat	ion Papers				
9)[The specification is objected to by the	e Examiner.			
10)[The drawing(s) filed on is/are:	a) accepted or b)	objected to by the	Examiner.	
	Applicant may not request that any obje	ction to the drawing(s) be	held in abeyance. Se	ee 37 CFR 1.85(a).	
_	Replacement drawing sheet(s) including	•	-,,	•	
11)[The oath or declaration is objected to	b by the Examiner. Not	e the attached Offic	e Action or form PTO-152.	
Priority	under 35 U.S.C. § 119				
	Acknowledgment is made of a claim All b) Some * c) None of: Certified copies of the priority Certified copies of the priority	documents have been documents have been	received. received in Applica	tion No	
	3. Copies of the certified copies	, ,		ed in this National Stage	
*	application from the Internation See the attached detailed Office action	•		red	
			od dopies nat resent	ou.	
Attachme	• •	·			
2) Noti 3) Info	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (F mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	PTO-948)	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Date	

Application/Control Number: 10/796,825

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

Claims 1-16 and 24-26 are generic to the following disclosed patentably distinct species: an endothelin-A receptor antagonist (sulfisoxazole, ABT-627); an opioids receptor agonist (morphine, codeine, hydrocodone or oxycodone); a GIRK channel activator; a protein kinase C activator. The species are independent or distinct because each of the agents above to be employed has different unrelated chemical/physical properties exhibiting unrelated mechanism of action resulting in different effects and unrelated structural moiety. Applicants are required under 35 U.S.C. 121 to elect a single disclosed ultimate species, even though this requirement is traversed. Applicants are advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicants are advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicants traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Kim Patent Examiner Art Unit 1617